Share-based Payment Arrangement, Expense of Olema Pharmaceuticals, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Olema Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Olema Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,250,000, a 24% decline year-over-year.
  • Olema Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $19,643,000, a 4.7% decline year-over-year.
  • Olema Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $22,582,000, a 31% increase from 2023.
  • Olema Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $17,256,000, a 8.4% decline from 2022.
  • Olema Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18,829,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Olema Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,643,000 $4,250,000 -$1,376,000 -24% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $21,019,000 $4,692,000 -$1,032,000 -18% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $22,051,000 $4,378,000 -$531,000 -11% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $22,582,000 $6,323,000 +$1,972,000 +45% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $20,610,000 $5,626,000 +$1,521,000 +37% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $19,089,000 $5,724,000 +$1,554,000 +37% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $17,535,000 $4,909,000 +$279,000 +6% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $17,256,000 $4,351,000 -$510,000 -10% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $17,766,000 $4,105,000 -$170,000 -4% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $17,936,000 $4,170,000 -$558,000 -12% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $18,494,000 $4,630,000 -$335,000 -6.7% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $18,829,000 $4,861,000 +$234,000 +5.1% 01 Oct 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
Q3 2022 $18,595,000 $4,275,000 +$118,000 +2.8% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $18,477,000 $4,728,000 +$807,000 +21% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $17,670,000 $4,965,000 +$1,757,000 +55% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $15,913,000 $4,627,000 01 Oct 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
Q3 2021 $4,157,000 +$3,575,000 +614% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $3,921,000 +$3,767,000 +2446% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $3,208,000 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q3 2020 $582,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $154,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2

Olema Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $22,582,000 +$5,326,000 +31% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $17,256,000 -$1,573,000 -8.4% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $18,829,000 +$2,916,000 +18% 01 Jan 2022 31 Dec 2022 10-K 11 Mar 2024 2023 FY
2021 $15,913,000 +$12,835,000 +417% 01 Jan 2021 31 Dec 2021 10-K 09 Mar 2023 2022 FY
2020 $3,078,000 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.